BMB Reports

Korean Society for Biochemistry and Molecular Biology (생화학분자생물학회)
권호 표지
DOI QR코드

DOI QR Code

Mechanistic insights into differential requirement of receptor dimerization for oncogenic activation of mutant EGFR and its clinical perspective

  • Cho, Jeonghee (Department of Nanobiomedical Science, Dankook University)
  • Received : 2020.02.03
  • Published : 2020.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

The epidermal growth factor receptor (EGFR), a member of the ErbB family (EGFR, ErbB2, ErbB3 and ErbB4), plays a crucial role in regulating various cellular responses such as proliferation, differentiation, and survival. As a result, aberrant activation of EGFR, mostly mediated through different classes of genomic alterations occurring within EGFR, is closely associated with the pathogenesis of numerous human cancers including lung adenocarcinoma, glioblastoma, and colorectal cancer. Thus, specific suppression of oncogenic activity of mutant EGFR with its targeted drugs has been routinely used in the clinic as a very effective anti-cancer strategy in treating a subset of tumors driven by such oncogenic EGFR mutants. However, the clinical efficacy of EGFR-targeted therapy does not last long due to several resistance mechanisms that emerge in the patients following the drug treatment. Thus, there is an urgent need for the development of novel therapeutic tactics specifically targeting mutant EGFR with the focus on the unique biological features of various mutant EGFR. Regarding this point, our review specifically emphasizes the recent findings about distinct requirements of receptor dimerization and autophosphorylation, which are critical steps for enzymatic activation of EGFR and signaling cascades, respectively, among wildtype and mutant EGFR and further discuss their clinical significance. In addition, the molecular mechanisms regulating EGFR dimerization and enzymatic activity by a key negative feedback inhibitor Mig6 as well as the clinical use for developing potential novel drugs targeting it are described in this review.

Keywords

References

  1. Olayioye MA, Neve RM, Lane HA and Hynes NE (2000) The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19, 3159-3167 https://doi.org/10.1093/emboj/19.13.3159
  2. Yarden Y and Pines G (2012) The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer 12, 553-563 https://doi.org/10.1038/nrc3309
  3. Schlessinger J and Lemmon MA (2006) Nuclear signaling by receptor tyrosine kinases: the first robin of spring. Cell 127, 45-48 https://doi.org/10.1016/j.cell.2006.09.013
  4. Burgess AW, Cho HS, Eigenbrot C et al (2003) An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 12, 541-552 https://doi.org/10.1016/S1097-2765(03)00350-2
  5. Schlessinger J (2000) Cell signaling by receptor tyrosine kinases. Cell 103, 211-225 https://doi.org/10.1016/S0092-8674(00)00114-8
  6. Sharma SV, Bell DW, Settleman J and Haber DA (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7, 169-181 https://doi.org/10.1038/nrc2088
  7. Lee JC, Vivanco I, Beroukhim R et al (2006) Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med 3, e485 https://doi.org/10.1371/journal.pmed.0030485
  8. Castellanos E, Feld E and Horn L (2017) Driven by mutations: The predictive value of mutation subtype in EGFR-Mutated non-small cell lung cancer. J Thorac Oncol 12, 612-623 https://doi.org/10.1016/j.jtho.2016.12.014
  9. Hirono Y, Tsugawa K, Fushida S et al (1995) Amplification of epidermal growth factor receptor gene and its relationship to survival in human gastric cancer. Oncology 52, 182-188 https://doi.org/10.1159/000227455
  10. al-Kasspooles M, Moore JH, Orringer MB and Beer DG (1993) Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas. Int J Cancer 54, 213-219 https://doi.org/10.1002/ijc.2910540209
  11. Gan HK, Cvrljevic AN and Johns TG (2013) The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered. FEBS J 280, 5350-5370 https://doi.org/10.1111/febs.12393
  12. Cho J, Pastorino S, Zeng Q et al (2011) Glioblastomaderived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies. Cancer Res 71, 7587-7596 https://doi.org/10.1158/0008-5472.CAN-11-0821
  13. Imielinski M, Berger AH, Hammerman PS et al (2012) Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150, 1107-1120 https://doi.org/10.1016/j.cell.2012.08.029
  14. Hynes NE and Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5, 341-354 https://doi.org/10.1038/nrc1609
  15. Harris RC, Chung E and Coffey RJ (2003) EGF receptor ligands. Exp Cell Res 284, 2-13 https://doi.org/10.1016/S0014-4827(02)00105-2
  16. Garrett TP, McKern NM, Lou M et al (2002) Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell 110, 763-773 https://doi.org/10.1016/S0092-8674(02)00940-6
  17. Ogiso H, Ishitani R, Nureki O et al (2002) Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 110, 775-787 https://doi.org/10.1016/S0092-8674(02)00963-7
  18. Cho HS and Leahy DJ (2002) Structure of the extracellular region of HER3 reveals an interdomain tether. Science 297, 1330-1333 https://doi.org/10.1126/science.1074611
  19. Cho HS, Mason K, Ramyar KX et al (2003) Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421, 756-760 https://doi.org/10.1038/nature01392
  20. Ferguson KM (2008) Structure-based view of epidermal growth factor receptor regulation. Annu Rev Biophys 37, 353-373 https://doi.org/10.1146/annurev.biophys.37.032807.125829
  21. Groenen LC, Walker F, Burgess AW and Treutlein HR (1997) A model for the activation of the epidermal growth factor receptor kinase involvement of an asymmetric dimer? Biochemistry 36, 3826-3836 https://doi.org/10.1021/bi9614141
  22. Zhang X, Gureasko J, Shen K, Cole PA and Kuriyan J (2006) An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125, 1137-1149 https://doi.org/10.1016/j.cell.2006.05.013
  23. De Bondt HL, Rosenblatt J, Jancarik J, Jones HD, Morgan DO and Kim SH (1993) Crystal structure of cyclin-dependent kinase 2. Nature 363, 595-602 https://doi.org/10.1038/363595a0
  24. Cho J, Bass AJ, Lawrence MS et al (2014) Colon cancerderived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab. Mol Cancer 13, 141 https://doi.org/10.1186/1476-4598-13-141
  25. Cho J, Chen L, Sangji N et al (2013) Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization. Cancer Res 73, 6770-6779 https://doi.org/10.1158/0008-5472.CAN-13-1145
  26. Kim N, Cho D, Kim H et al (2020) Colorectal adenocarcinoma-derived EGFR mutants are oncogenic and sensitive to EGFR-targeted monoclonal antibodies, cetuximab and panitumumab. Int J Cancer 146, 2194-2200 https://doi.org/10.1002/ijc.32499
  27. Park AK, Francis JM, Park WY, Park JO and Cho J (2015) Constitutive asymmetric dimerization drives oncogenic activation of epidermal growth factor receptor carboxylterminal deletion mutants. Oncotarget 6, 8839-8850 https://doi.org/10.18632/oncotarget.3559
  28. Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350, 2129-2139 https://doi.org/10.1056/NEJMoa040938
  29. Paez JG, Janne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 https://doi.org/10.1126/science.1099314
  30. Pao W, Miller V, Zakowski M et al (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101, 13306-13311 https://doi.org/10.1073/pnas.0405220101
  31. Greulich H, Chen TH, Feng W et al (2005) Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med 2, e313 https://doi.org/10.1371/journal.pmed.0020313
  32. Yun CH, Boggon TJ, Li Y et al (2007) Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 11, 217-227 https://doi.org/10.1016/j.ccr.2006.12.017
  33. Guo G, Gong K, Wohlfeld B, Hatanpaa KJ, Zhao D and Habib AA (2015) Ligand-Independent EGFR Signaling. Cancer Res 75, 3436-3441 https://doi.org/10.1158/0008-5472.CAN-15-0989
  34. Chan SK, Gullick WJ and Hill ME (2006) Mutations of the epidermal growth factor receptor in non-small cell lung cancer -- search and destroy. Eur J Cancer 42, 17-23 https://doi.org/10.1016/j.ejca.2005.07.031
  35. Sequist LV, Martins RG, Spigel D et al (2008) First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 26, 2442-2449 https://doi.org/10.1200/JCO.2007.14.8494
  36. Francis JM, Zhang CZ, Maire CL et al (2014) EGFR variant heterogeneity in glioblastoma resolved through singlenucleus sequencing. Cancer Discov 4, 956-971 https://doi.org/10.1158/2159-8290.CD-13-0879
  37. Cho J, Kim S, Du J and Meyerson M (2018) Autophosphorylation of the carboxyl-terminal domain is not required for oncogenic transformation by lung-cancer derived EGFR mutants. Int J Cancer 143, 679-685 https://doi.org/10.1002/ijc.31332
  38. Wang Z (2017) ErbB receptors and cancer. Methods Mol Biol 1652, 3-35 https://doi.org/10.1007/978-1-4939-7219-7_1
  39. Sorkin A and Goh LK (2009) Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res 315, 683-696 https://doi.org/10.1016/j.yexcr.2008.07.029
  40. Segatto O, Anastasi S and Alema S (2011) Regulation of epidermal growth factor receptor signalling by inducible feedback inhibitors. J Cell Sci 124, 1785-1793 https://doi.org/10.1242/jcs.083303
  41. Anastasi S, Lamberti D, Alema S and Segatto O (2016) Regulation of the ErbB network by the MIG6 feedback loop in physiology, tumor suppression and responses to oncogene-targeted therapeutics. Semin Cell Dev Biol 50, 115-124 https://doi.org/10.1016/j.semcdb.2015.10.001
  42. Anastasi S, Fiorentino L, Fiorini M et al (2003) Feedback inhibition by RALT controls signal output by the ErbB network. Oncogene 22, 4221-4234 https://doi.org/10.1038/sj.onc.1206516
  43. Hackel PO, Gishizky M and Ullrich A (2001) Mig-6 is a negative regulator of the epidermal growth factor receptor signal. Biol Chem 382, 1649-1662 https://doi.org/10.1515/BC.2001.20
  44. Anastasi S, Baietti MF, Frosi Y, Alema S and Segatto O (2007) The evolutionarily conserved EBR module of RALT/MIG6 mediates suppression of the EGFR catalytic activity. Oncogene 26, 7833-7846 https://doi.org/10.1038/sj.onc.1210590
  45. Zhang X, Pickin KA, Bose R, Jura N, Cole PA and Kuriyan J (2007) Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. Nature 450, 741-744 https://doi.org/10.1038/nature05998
  46. Park E, Kim N, Ficarro SB et al (2015) Structure and mechanism of activity-based inhibition of the EGF receptor by Mig6. Nat Struct Mol Biol 22, 703-711 https://doi.org/10.1038/nsmb.3074
  47. Ying H, Zheng H, Scott K et al (2010) Mig-6 controls EGFR trafficking and suppresses gliomagenesis. Proc Natl Acad Sci U S A 107, 6912-6917 https://doi.org/10.1073/pnas.0914930107
  48. Frosi Y, Anastasi S, Ballaro C et al (2010) A two-tiered mechanism of EGFR inhibition by RALT/MIG6 via kinase suppression and receptor degradation. J Cell Biol 189, 557-571 https://doi.org/10.1083/jcb.201002032
  49. Ferby I, Reschke M, Kudlacek O et al (2006) Mig6 is a negative regulator of EGF receptor-mediated skin morphogenesis and tumor formation. Nat Med 12, 568-573 https://doi.org/10.1038/nm1401
  50. Broadbridge VT, Karapetis CS and Price TJ (2012) Cetuximab in metastatic colorectal cancer. Expert Rev Anticancer Ther 12, 555-565 https://doi.org/10.1586/era.12.25
  51. Dokala A and Thakur SS (2017) Extracellular region of epidermal growth factor receptor: a potential target for anti-EGFR drug discovery. Oncogene 36, 2337-2344 https://doi.org/10.1038/onc.2016.393
  52. Valley CC, Arndt-Jovin DJ, Karedla N et al (2015) Enhanced dimerization drives ligand-independent activity of mutant epidermal growth factor receptor in lung cancer. Mol Biol Cell 26, 4087-4099 https://doi.org/10.1091/mbc.E15-05-0269
  53. Maity TK, Venugopalan A, Linnoila I et al (2015) Loss of MIG6 accelerates initiation and progression of mutant epidermal growth factor receptor-driven lung adenocarcinoma. Cancer Discov 5, 534-549 https://doi.org/10.1158/2159-8290.CD-14-0750
  54. Westover D, Zugazagoitia J, Cho BC, Lovly CM and Paz-Ares L (2018) Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol 29, i10-i19 https://doi.org/10.1093/annonc/mdx703
  55. Tan CS, Kumarakulasinghe NB, Huang YQ et al (2018) Third generation EGFR TKIs: current data and future directions. Mol Cancer 17, 29 https://doi.org/10.1186/s12943-018-0778-0
  56. Wang S, Tsui ST, Liu C, Song Y and Liu D (2016) EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer. J Hematol Oncol 9, 59 https://doi.org/10.1186/s13045-016-0290-1
  57. Gerhart J, Thevenin AF, Bloch E, King KE and Thevenin D (2018) Inhibiting epidermal growth factor receptor dimerization and signaling through targeted delivery of a juxtamembrane domain peptide mimic. ACS Chem Biol 13, 2623-2632 https://doi.org/10.1021/acschembio.8b00555
  58. Li N and Wei M (2017) Conversion of MIG6 peptide from the nonbinder to binder of lung cancer-related EGFR by phosphorylation and cyclization. Artif Cells Nanomed Biotechnol 45, 1023-1028 https://doi.org/10.1080/21691401.2016.1200058
  59. Yu XD, Yang R and Leng CJ (2016) Truncation, modification, and optimization of MIG6(segment 2) peptide to target lung cancer-related EGFR. Comput Biol Chem 61, 251-257 https://doi.org/10.1016/j.compbiolchem.2016.02.015
  60. Frederick L, Wang XY, Eley G and James CD (2000) Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 60, 1383-1387
  61. Barber TD, Vogelstein B, Kinzler KW and Velculescu VE (2004) Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med 351, 2883 https://doi.org/10.1056/NEJM200412303512724
  62. Yamazaki H, Fukui Y, Ueyama Y et al (1988) Amplification of the structurally and functionally altered epidermal growth factor receptor gene (c-erbB) in human brain tumors. Mol Cell Biol 8, 1816-1820 https://doi.org/10.1128/MCB.8.4.1816
  63. Huang SF, Liu HP, Li LH et al (2004) High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 10, 8195-8203 https://doi.org/10.1158/1078-0432.CCR-04-1245
  64. Sasaki H, Okuda K, Takada M et al (2008) A novel EGFR mutation D1012H and polymorphism at exon 25 in Japanese lung cancer. J Cancer Res Clin Oncol 134, 1371-1376 https://doi.org/10.1007/s00432-008-0411-5
  65. Balak MN, Gong Y, Riely GJ et al (2006) Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 12, 6494-6501 https://doi.org/10.1158/1078-0432.CCR-06-1570
  66. Asahina H, Yamazaki K, Kinoshita I, Yokouchi H, Dosaka- Akita H and Nishimura M (2006) Non-responsiveness to gefitinib in a patient with lung adenocarcinoma having rare EGFR mutations S768I and V769L. Lung Cancer 54, 419-422 https://doi.org/10.1016/j.lungcan.2006.09.005
  67. Tokumo M, Toyooka S, Ichihara S et al (2006) Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer. Lung Cancer 53, 117-121 https://doi.org/10.1016/j.lungcan.2006.04.008
  68. Han SW, Kim TY, Hwang PG et al (2005) Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 23, 2493-2501 https://doi.org/10.1200/JCO.2005.01.388
  69. Montagut C, Dalmases A, Bellosillo B et al (2012) Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med 18, 221-223 https://doi.org/10.1038/nm.2609
  70. Kohsaka S, Nagano M, Ueno T et al (2017) A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer. Sci Transl Med 9, pii: eaan6566
  71. Sanchez-Martin FJ, Bellosillo B, Gelabert-Baldrich M et al (2016) The First-in-class Anti-EGFR antibody mixture sym004 overcomes cetuximab resistance mediated by EGFR extracellular domain mutations in colorectal cancer. Clin Cancer Res 22, 3260-3267 https://doi.org/10.1158/1078-0432.CCR-15-2400
  72. Arena S, Bellosillo B, Siravegna G et al (2015) Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer. Clin Cancer Res 21, 2157-2166 https://doi.org/10.1158/1078-0432.CCR-14-2821